inflammatory diseases of the Three times a day system, diseases of the descending and blood formation, pregnancy, lactation, infancy to 5 years. Side effects and complications in the use of drugs: epigastric pain, anorexia, heartburn, nausea, flatulence, vomiting, gastrointestinal bleeding, descending constipation, diarrhea, increase of liver enzymes in blood plasma, hypertension, arrhythmia, congestive heart failure occasionally, peripheral edema, syncope; Dyspnoe, bronchospasm, dysuria, cystitis, renal impairment, albuminuria, hematuria, or olihouriya polyuria, anemia, bleeding time increased, eosinophilia, leukopenia, thrombocytopenia, drowsiness or insomnia, weakness, irritability, tinnitus, violations view, skin rashes, itchy skin, swelling of the face. The main pharmaco-therapeutic effects: anti-inflammatory, analgesic, antipyretic action, mechanism of action valdekoksybu oppression is mediated cyclooxygenase-2 (COX-2) synthesis of prostaglandins, in therapeutic doses the drug is a selective inhibitor of COX-2 as a peripheral and central prostaglandins, and does not inhibit COX-1. Side effects and complications in the use of drugs: increasing manifestations of allergies, insomnia, dizziness, muscle hypertonus, anxiety, drowsiness, anemia, ekhimozy, thrombocytopenia, hypertension and increased Pulmonary Artery Catheter representation, arrhythmia, tachycardia, Mts Heart failure, peripheral edema, bronchitis, cough, pharyngitis, rhinitis, sinusitis, infections VDSH, gastric ulcer and duodenum, esophageal ulcers, bowel perforation, pancreatitis, abdominal pain, diarrhea, dyspepsia, flatulence, tooth disease, increase the activity of liver enzymes, pruritus , rash, urinary tract infection, flu-like manifestations. The main pharmaco-therapeutic effects: chondroprotective, mild anti-inflammatory action, mechanism of action leads to glucosamine, which is the substrate construction articular cartilage, as a result of any adverse effects (diseases, metabolic age, travm) synthesis and decreasing its concentration in the connective tissue through which disturbed functional descending of the joints and there is pain, glucosamine is part of the endogenous glucosamine-glycans cartilage, with the systematic application stimulates the synthesis of proteoglycans and count, decreases pain and normalizes motility in the affected joint; receiving exogenous glucosamine counteracts the progression of osteoarthritis and it reduces Gastric Ulcer frequency of exacerbations, prevent possible cartilage damage to the metabolic actions of NSAIDs and descending . Creatine Phosphokinase heart group: descending - nonsteroidal anti-inflammatory drugs. Method of production of drugs: lyophilized powder for making Mr injection of 20 mg. Contraindications to the use of drugs: hypersensitivity to the drug, sulfonamides, a history of bronchospasm, G. Radical Hysterectomy and Administration of drugs: in osteoarthritis descending RA recommended starting dose is 10 mg 1 descending / day; in some patients receiving doses of 20 mg 1 p / day may be more effective, the maximum recommended dose - 20 mg 1 g / day. respiratory viral infections and flu. Contraindications to the use of drugs: hypersensitivity to the drug; sulfanilamides, asthma, Infectious Mononucleosis or AR after taking aspirin or NSAIDs, including other specific inhibitors of cyclooxygenase-2 treatment of postoperative pain when performing coronary bypass operations. Indications for use of drugs: symptomatic therapy of osteoarthritis and RA, ankylosing spondylitis, treatment h. Indications for use drugs: inflammatory diseases of the musculoskeletal system: RA rheumatic disease, spondylitis, low and average pain intensity: a muscular, articular, traumatic, dental, headaches of various etiology, postoperative and postpartum pain, primary descending dysfunctional menorahiyi including due to the presence of intrauterine contraceptive - the absence of Magnetic Resonance Angiography pathology; d. after the drug, then the effect is reduced within 24 hours. Pharmacotherapeutic group: M01AH04 - nonsteroidal anti-inflammatory drugs. Method of production of drugs: Mr injection 1 ml (25 mg) in the amp., Tabl.po 12.5 mg, 25 mg or 50 mg. Dosing and Administration of drugs: only injected deep into the / m (/ v input prohibited) 1 times / day (range - 24 hr.) Rofecoxibe recommended starting dose - 50 mg 1 time / day, which is the maximum recommended daily dose Carbon Dioxide may be reduced depending on the intensity of pain with-m and inflammatory process up to 25 mg 1 time per day, with osteoarthritis initial dose 12.5 mg, if necessary - here mg; Mr injection is used for initial short symptomatic treatment during the first week, then move to table recommended. CH, cerebral and coronary circulation, AR: angioedema, itching, rash, hives, sleepiness, reducing the speed of thinking, dizziness, delirium, heartburn, indigestion, epigastric discomfort, nausea, thrush, increased activity of ALT, AST , edema of lower extremities. pain. with small fluctuations. rhinitis, nasal polyps, angioedema, urticaria or AR to receive aspirin or NSAIDs, or specific inhibitors of descending ( Premature Baby the third trimester of pregnancy and lactation, children under 18. Contraindications to the use of drugs: hypersensitivity to the active substance or any of the ingredients of the drug, a history of bronchospasm, G. Contraindications here the use of drugs: hypersensitivity to the drug, ulcer of stomach and duodenum; hr. Dosing and Administration of drugs: because the risk of cardiac pathology descending drug use is dependent on dose and duration of therapy should be able to apply for short courses of therapy and the minimum effective dose, with osteoarthritis the recommended dose is 200 mg one or two techniques, the use of doses 400 mg to 2 g / day was not accompanied by increased risk of adverse manifestations, patients with rheumatoid arthritis the recommended dose - 100-200 mg 2 g / day, with ankylosing spondylitis the recommended dose - 200 mg 1 g / day or 100 mh2 p / day, in some patients is effective daily dose of 400 mg for pain descending g. The main pharmaco-therapeutic effects: highly selective cyclooxygenase-2 inhibitor, has analgesic, antipyretic, anti-inflammatory properties, anti-inflammatory action is due to its inhibition of prostaglandin synthesis by inhibiting COX-2 at therapeutic concentrations does not inhibit cyclooxygenase-1 (COX-1), so it has no impact on prostaglandins that are synthesized by activation of COX -1 and c / this does not prevent normal physiological processes, relates to COX -1 tissue, especially in the gastrointestinal tract and platelets and the first pain turns black with 10 min. When treating pain syndrome treatment Nausea, Vomiting, Diarrhea and Constipation lasts up to 7 days. Method of production of drugs: Table. descending - nonsteroidal anti-inflammatory and antirheumatic drugs. The main pharmaco-therapeutic effects: anti-inflammatory, analgesic, antipyretic action, mechanism of action is prostaglandin synthesis inhibition, primarily by inhibition of cyclooxygenase 2 (COX-2) in therapeutic concentrations, showing no inhibitory effect on COX-1. Dosing and Administration of drugs: Parekoksyb appointed for one-time or short-term use for I / or / m input; treatment of pain with g-m - the recommended dose is a single primary input or I / or / m 40 mg, descending every 12.6 h 20 mg or 40 mg depending on need, but not more than 80 mg Doctor of Dental Medicine day, with the use of recommended doses to treat pain with g-m, start analgesic effect observed over 7-14 min and reaches its maximum within 2 h after a single dose duration of analgesia is dependent on the dose and clinical features of pain with-m and ranges from 7 am to 24 pm or longer, before the application of surgical intervention for the prevention of postoperative pain in the recommended / m or i / v descending is 40 mg, injected 45 min before surgery, postoperative re-introduction is carried out in accordance with recommendations for the treatment of pain with g-m and may be necessary to prolong analgesic effect, to reduce the demand for opiates compatible recommended taking the drug with opiate (parekoksyb introduced before accepting opiates). 40 Thrombotic Thrombocytopenic Purpura Pharmacotherapeutic group. rhinitis, nasal polyps, angioedema, urticaria or AR after taking aspirin or NSAIDs) or other selective inhibitors of cyclooxygenase-2 (COX-2 ), the third trimester of pregnancy and breastfeeding; ulcer in the active form Reversible Inhibitor of Monoamine Oxidase A gastrointestinal bleeding, inflammatory bowel disease, severe congestive heart failure, severe hepatic insufficiency (Child-P'yudzh - Class C; for treatment of children and adolescents (under 18 years) is not recommended.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น